AU2001263130A1 - Bicyclic cyclohexylamines and their use as nmda receptor antagonists - Google Patents

Bicyclic cyclohexylamines and their use as nmda receptor antagonists

Info

Publication number
AU2001263130A1
AU2001263130A1 AU2001263130A AU6313001A AU2001263130A1 AU 2001263130 A1 AU2001263130 A1 AU 2001263130A1 AU 2001263130 A AU2001263130 A AU 2001263130A AU 6313001 A AU6313001 A AU 6313001A AU 2001263130 A1 AU2001263130 A1 AU 2001263130A1
Authority
AU
Australia
Prior art keywords
nmda receptor
cyclohexylamines
bicyclic
receptor antagonists
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001263130A
Inventor
Russell Joseph Deorazio
Sham Shridhar Nikam
Ian Leslie Scott
Brian Alan Sherer
Lawrence David Wise
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of AU2001263130A1 publication Critical patent/AU2001263130A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms

Abstract

Described are heterocycle-substituted cyclohexylamines of formula (I), and their pharmaceutically acceptable salts thereof. The compounds of the formula (I) are antagonists of NMDA receptor channel complexes useful for treating cerebral vascular disorders such as, for example, cerebral ischemia, cardiac arrest, stroke, and Parkinson's disease,
AU2001263130A 2000-06-06 2001-05-14 Bicyclic cyclohexylamines and their use as nmda receptor antagonists Abandoned AU2001263130A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20948500P 2000-06-06 2000-06-06
US60209485 2000-06-06
PCT/US2001/015605 WO2001094321A1 (en) 2000-06-06 2001-05-14 Bicyclic cyclohexylamines and their use as nmda receptor antagonists

Publications (1)

Publication Number Publication Date
AU2001263130A1 true AU2001263130A1 (en) 2001-12-17

Family

ID=22778928

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001263130A Abandoned AU2001263130A1 (en) 2000-06-06 2001-05-14 Bicyclic cyclohexylamines and their use as nmda receptor antagonists

Country Status (11)

Country Link
US (1) US6683101B2 (en)
EP (1) EP1292581B1 (en)
JP (1) JP2003535851A (en)
AT (1) ATE301642T1 (en)
AU (1) AU2001263130A1 (en)
BR (1) BR0111267A (en)
CA (1) CA2407164A1 (en)
DE (1) DE60112574T2 (en)
ES (1) ES2243500T3 (en)
MX (1) MXPA02010503A (en)
WO (1) WO2001094321A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10210779A1 (en) * 2002-03-12 2003-10-09 Merck Patent Gmbh Cyclic amides
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
ES2523017T3 (en) * 2004-03-03 2014-11-20 Glaxosmithkline Llc Aniline derivatives as selective modulators of androgen receptors
JPWO2007063839A1 (en) * 2005-11-30 2009-05-07 塩野義製薬株式会社 Cyclohexane derivative
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
JP5523107B2 (en) 2006-11-30 2014-06-18 プロビオドルグ エージー Novel inhibitors of glutaminyl cyclase
NZ579310A (en) 2007-03-01 2012-03-30 Probiodrug Ag Use of glutaminyl cyclase inhibitors for the treatment of mild cognitive impairment and diagnostic purposes thereof
EP2142514B1 (en) 2007-04-18 2014-12-24 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
EP2288615B1 (en) 2008-05-21 2017-06-21 Genesis Technologies Limited Selective caspase inhibitors and uses thereof
CA2772488C (en) 2009-09-11 2018-04-17 Probiodrug Ag Heterocyclic derivatives as inhibitors of glutaminyl cyclase
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
US8269019B2 (en) 2010-03-10 2012-09-18 Probiodrug Ag Inhibitors
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
JP6050264B2 (en) 2011-03-16 2016-12-21 プロビオドルグ エージー Benzimidazole derivatives as inhibitors of glutaminyl cyclase
CN105153020A (en) * 2015-07-20 2015-12-16 湖南华腾制药有限公司 Preparation method for aromatic azide
PL3461819T3 (en) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitors of glutaminyl cyclase

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4239151A1 (en) 1992-11-20 1994-05-26 Thomae Gmbh Dr K N, N-disubstituted arylcycloalkylamines, their salts, medicaments containing them and their use, and processes for their preparation
WO1997015549A1 (en) * 1995-10-26 1997-05-01 Tokyo Tanabe Company Limited PHENYLETHANOLAMINE COMPOUNDS USEFUL AS β3 AGONIST, PROCESS FOR PRODUCING THE SAME, AND INTERMEDIATES IN THE PRODUCTION OF THE SAME
DE19812331A1 (en) 1998-03-20 1999-09-23 Merck Patent Gmbh New benzo-heterocyclic substituted piperidine derivatives useful as excitatory aminoacid receptor antagonists, used e.g. for treating neurodegenerative diseases
EP0982026B1 (en) 1998-08-18 2006-05-17 F. Hoffmann-La Roche Ag Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers
US6184236B1 (en) * 1998-08-18 2001-02-06 Hoffmann-La Roche Inc. Method of treating a neurodegenerative disease by administering an aryl-cyclohexylamine derivative
MXPA02002749A (en) * 2001-03-27 2002-10-28 Warner Lambert Co Cyclohexylamine derivatives as subtype selective n-methyl-d-aspartate antagonists.

Also Published As

Publication number Publication date
ES2243500T3 (en) 2005-12-01
US20030232810A1 (en) 2003-12-18
BR0111267A (en) 2003-12-16
ATE301642T1 (en) 2005-08-15
CA2407164A1 (en) 2001-12-13
EP1292581B1 (en) 2005-08-10
WO2001094321A1 (en) 2001-12-13
MXPA02010503A (en) 2003-03-10
US6683101B2 (en) 2004-01-27
DE60112574D1 (en) 2005-09-15
JP2003535851A (en) 2003-12-02
DE60112574T2 (en) 2006-06-08
EP1292581A1 (en) 2003-03-19

Similar Documents

Publication Publication Date Title
AP2002002664A0 (en) Cyclohexylamine derivative as subtype selective NMDA receptor antagonists.
AU2001263130A1 (en) Bicyclic cyclohexylamines and their use as nmda receptor antagonists
AP2002002697A0 (en) Biciclic cyclohexylamines and their use as NMDA receptor antagonists.
WO2003037860A3 (en) Purine analogs having hsp90-inhibiting activity
NZ522326A (en) Adenosine A2A receptor antagonists
CA2492804A1 (en) Novel inhibitors of kinases
UA83101C2 (en) 2,6-bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists
CA2509650A1 (en) C-6 modified indazolylpyrrolotriazines
YU64303A (en) N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
WO2003048164A3 (en) Adenosine a2a receptor antagonists
WO2002072536A8 (en) Urea derivatives having vanilloid receptor (vr1) antagonist activity
IL114599A (en) Substituted pyrimidine compounds their preparation and pharmaceutical compositions containg them
CA2468649A1 (en) Adenosine a2a receptor antagonists
CA2368823A1 (en) Use of dopamine d3 receptor ligands for producing medicaments for treating kidney disorders
ZA200201788B (en) Substituted 1,5-dihydropyrrol-2-on derivatives as NMDA receptor antagonists for the treatment of pain.
MX344556B (en) 5-ht1a.
MXPA04004606A (en) Solubilized topoisomerase poisons.
WO2002050070A3 (en) Piperidine derivatives as subtype selective n-methyl-d-aspartate antagonists
AU2002364953A1 (en) Topoisomerase poison agents
EP1453507A4 (en) Solubilized topoisomerase poison agents
MXPA03000439A (en) Novel form of (r)-n-[5- methyl-8-(4- methylpiperazin-1-yl) -1, 2, 3, 4-tetrahydro -2-naphthyl] -4-morpholinobenzamide.
AU9139791A (en) Use of quisqualate-receptor antagonists for treating Parkinson's disease
NZ533358A (en) 3,4-Dihydro-1H-isoquinolin-2-yl-derivatives for use as NK2 receptor antagonists
ZA986971B (en) 4-Aminopyrrole (3,2-D) pyrimidines as neuropeptide Y receptor antagonists.